Related Experiment Video
Updated: Jul 29, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Acute heart failure with mildly reduced ejection fraction and myocardial infarction: a multi-institutional cohort
Ming-Shyan Lin1,2,3, Po-Chang Wang1, Meng-Hung Lin4
1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital Chiayi Branch, Chiayi, Taiwan.
Insights
Patients with heart failure with mid-range ejection fraction (HFmrEF) face higher risks of myocardial infarction. Further large-scale research is needed to understand HFmrEF and ischemic cardiomyopathy, guiding optimal anti-ischemic treatments.
Area of Science:
- Cardiology
- Heart Failure Research
- Ischemic Outcomes
Background:
- Limited research exists on ischemic outcomes in acute decompensated heart failure (ADHF) related to left ventricular ejection fraction (EF).
- Understanding these outcomes is crucial for managing ADHF patients.
Purpose of the Study:
- To investigate ischemic outcomes in patients with different ranges of left ventricular ejection fraction (EF) within acute decompensated heart failure (ADHF).
- To compare the clinical outcomes, including cardiovascular mortality and rehospitalization, among patients with heart failure with preserved ejection fraction (HFpEF), mid-range ejection fraction (HFmrEF), and reduced ejection fraction (HFrEF).
Main Methods:
- A retrospective cohort study utilizing the Chang Gung Research Database from 2001 to 2021.
- Inclusion of ADHF patients discharged between January 1, 2005, and December 31, 2019.
- Primary outcomes included cardiovascular mortality and heart failure rehospitalization, with secondary outcomes of all-cause mortality, acute myocardial infarction (AMI), and stroke.
Main Results:
- A cohort of 12,852 ADHF patients was analyzed, with 2,222 (17.3%) classified as HFmrEF.
- HFmrEF patients exhibited a higher prevalence of comorbidities like diabetes, dyslipidemia, and ischemic heart disease compared to HFrEF and HFpEF.
- HFmrEF patients had the highest rate of AMI (13.6%) compared to HFpEF (9.3%) and HFrEF (9.9%), indicating an increased risk.
Conclusions:
- Acute decompensation in HFmrEF patients is associated with an elevated risk of myocardial infarction.
- Further large-scale research is warranted to explore the relationship between HFmrEF and ischemic cardiomyopathy.
- Optimal anti-ischemic treatment strategies for HFmrEF require additional investigation.
Background:
Little research has been done on ischemic outcomes related to left ventricular ejection fraction (EF) in acute decompensated heart failure (ADHF).
Methods:
A retrospective cohort study was conducted between 2001 and 2021 using the Chang Gung Research Database. ADHF Patients discharged from hospitals between January 1, 2005, and December 31, 2019. Cardiovascular (CV) mortality and heart failure (HF) rehospitalization are the primary outcome components, along with all-cause mortality, acute myocardial infarction (AMI) and stroke.
Results:
A total of 12,852 ADHF patients were identified, of whom 2,222 (17.3%) had HFmrEF, the mean (SD) age was 68.5 (14.6) years, and 1,327 (59.7%) were males. In comparison with HFrEF and HFpEF patients, HFmrEF patients had a significant phenotype comorbid with diabetes, dyslipidemia, and ischemic heart disease. Patients with HFmrEF were more likely to experience renal failure, dialysis, and replacement. Both HFmrEF and HFrEF had similar rates of cardioversion and coronary interventions. There was an intermediate clinical outcome between HFpEF and HFrEF, but HFmrEF had the highest rate of AMI (HFpEF, 9.3%; HFmrEF, 13.6%; HFrEF, 9.9%). The AMI rates in HFmrEF were higher than those in HFpEF (AHR, 1.15; 95% Confidence Interval, 0.99 to 1.32) but not in HFrEF (AHR, 0.99; 95% Confidence Interval, 0.87 to 1.13).
Conclusion:
Acute decompression in patients with HFmrEF increases the risk of myocardial infarction. The relationship between HFmrEF and ischemic cardiomyopathy, as well as optimal anti-ischemic treatment, requires further research on a large scale.
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations
Heart Failure V: Medical Management

